The Tachykinin Peptide Family: Substance P, NKA, NKB and the NK1-NK3 Receptors

Three different peptides, one shared chemical handshake. That's the simplest way to describe the tachykinins—a family whose members look distinct on paper yet all end in the same short sequence and all speak to the same set of receptors. The compounds discussed here are for research use only, and this article is an educational overview of the biochemistry, not a guide to any use in humans or animals. If you're researching this peptide family, the tachykinins are worth knowing because they sit behind some of the most heavily studied signaling in the nervous and immune systems: pain transmission, neurogenic inflammation, even the hypothalamic timing of reproduction. Below we walk through what the three peptides are, the motif that unites them, the three neurokinin receptors and their preferences, how those receptors switch on at the molecular level, and why the family remains a long-running subject of laboratory research.

Meet the Tachykinins: Substance P, NKA, and NKB

The short version: the tachykinins are a family of small signaling peptides named for their fast ("tachy") action on smooth muscle, and in mammals the three best-characterized members are substance P, neurokinin A, and neurokinin B.

Substance P is the founding member and the one most researchers meet first. It's an 11-amino-acid peptide expressed across the central nervous system, the peripheral nervous system, and immune cells, and it's encoded by the TAC1 gene. That same TAC1 gene also produces neurokinin A, along with two extended forms called neuropeptide K and neuropeptide gamma. Neurokinin B comes from a different gene entirely—TAC3—while a third gene, TAC4, encodes still more family members such as hemokinin-1 and the endokinins.

What makes this a "family" isn't shared geography in the body but shared chemistry. Each of these peptides is built to interact with the same class of receptors, and each carries the same structural signature at its tail end. That signature is where the family definition really lives.

The FxGLM Motif: One Shared Ending, Three Peptides

The plain-English answer to "why are these one family?" is that they all finish with the same five-residue ending, and that ending is what the receptors read.

Every tachykinin terminates in the conserved sequence Phe-X-Gly-Leu-Met-NH₂, usually written as the FxGLM motif (the "x" is a variable hydrophobic residue). The final methionine is capped with an amidated C-terminus rather than a free acid. That small chemical detail turns out to be essential: the amidated tail reaches deep into the receptor and is required for activation. Strip or alter it and the peptide can no longer switch the receptor on.

Here's the elegant part. The shared C-terminal motif drives the general "turn the receptor on" function, but it does not decide which receptor a peptide prefers. That job falls to the residues sitting in front of the motif—the N-terminal portion of each peptide, which differs from one tachykinin to the next. Researchers have shown that the interactions between those upstream residues and the receptor explain both the family's shared activity and each member's individual preferences, a relationship confirmed through structural work on the NK1 and NK2 receptors. This "shared ending, variable front" architecture recurs across peptide biology; the RFamide peptide family is defined the same way, by a conserved C-terminal motif rather than any single function.

Three Receptors, Three Preferences: NK1, NK2, NK3

In short: there are three neurokinin receptors, all G-protein-coupled, and each has a favorite tachykinin—though "favorite" is a matter of degree, not an on/off switch.

The rank orders

The three receptors are named NK1, NK2, and NK3, and each shows a preferential affinity for one of the peptides: NK1 leans toward substance P, NK2 toward neurokinin A, NK3 toward neurokinin B. But because all three peptides carry the same active ending, every receptor can respond to every tachykinin—just with different strength. In binding studies the rank orders come out as NK1 (SP > NKA > NKB), NK2 (NKA > NKB > SP), and NK3 (NKB > NKA > SP). The family members aren't locked to a single partner; they overlap.

Cross-reactivity is asymmetric

What's striking is how uneven that overlap is. Work on the NK1 and NK2 receptors found that substance P's affinity for NK2 drops roughly 1,700-fold compared with neurokinin A's, yet neurokinin A's affinity for NK1 falls only about 37-fold relative to substance P's. So neurokinin A is a fairly capable NK1 visitor, while substance P is a poor guest at NK2. Structurally, this selectivity traces to a couple of specific receptor regions: charged residues on the second extracellular loop (an arginine in NK1, a lysine in NK2) that grip the peptide, plus a short stretch near the receptor's N-terminus. Swapping those regions between receptors flips the binding preferences—strong evidence that they're the real selectivity switches.

How the Receptors Switch On

The practical question here: what actually happens, structurally, when a tachykinin docks into its receptor? Recent structural biology has made the answer surprisingly concrete.

When the FxGLM tail settles into the receptor's binding pocket, a single residue near the bottom of that pocket does a lot of the work. In NK1 this position is a phenylalanine; in NK2 and NK3 it's a tyrosine, and that one-letter difference tunes how potently each receptor responds. Just above it sits a "toggle switch" tryptophan that flips its position on activation. Cryo-electron microscopy of substance P bound to its receptor shows the extracellular pocket contracting inward while, on the other side of the membrane, part of the receptor swings outward to open a docking site for the G protein. Mutating single residues between NK1 and NK2 measurably shifts both potency and efficacy, which pins these structural features to real function—as detailed in molecular studies of NK1 and NK2 activation.

Once the receptor is active, the signal it sends depends on the tissue. In some cell types tachykinin receptors couple to phospholipase C and calcium signaling; in others they change cyclic AMP levels. After signaling, the receptor is pulled back into the cell, a process driven in part by beta-arrestin recruitment—the same regulatory machinery labs measure to read GPCR behavior in vitro. Meanwhile the free peptide is broken down quickly by enzymes, giving substance P a working life measured in seconds to minutes in tissue, as summarized in the substance P biochemistry literature.

Substance P in Pain and Neurogenic Inflammation

Why does substance P get so much attention? Because in research models it sits at the crossroads of pain signaling and inflammation—two areas where understanding the messenger has obvious appeal.

In studies of pain transmission, sensory nerve fibers release substance P together with the neurotransmitter glutamate into the spinal cord's dorsal horn. The prevailing model, drawn from decades of laboratory work, is that substance P sensitizes the receiving neurons to glutamate, effectively turning up the volume on pain signals traveling toward the brain. That's an observed-in-research mechanism, not a statement about any individual's experience.

Substance P is also a central player in what researchers call neurogenic inflammation—the crosstalk between nerves and the immune system. Released at a site of tissue irritation, it can trigger mast cells to degranulate, relax the smooth muscle in small blood vessels, and draw immune cells toward the area, producing the familiar redness-and-swelling "wheal and flare" response. Mice engineered to lack the NK1 receptor show impaired neutrophil migration to inflamed tissue, a finding that helped establish substance P's role in immune recruitment. All of this is documented in the biochemistry of substance P, and all of it describes what has been seen in animal models and cell systems.

Neurokinin B, NK3R, and the Reproductive Pulse Generator

Neurokinin B is the quieter sibling in most discussions, but it has a distinct and remarkable claim to fame in the hypothalamus.

Deep in the brain's arcuate nucleus sits a population of neurons that co-express three signaling molecules at once: kisspeptin, neurokinin B, and dynorphin—known collectively as KNDy neurons. The dynorphin component ties this system to the broader dynorphin and the opioid peptides, which supply the "off" signal that ends each burst. According to research on KNDy neurons and the GnRH pulse generator, neurokinin B acting through the NK3 receptor helps synchronize these neurons so they fire in coordinated bursts, releasing kisspeptin, which in turn drives the pulsatile release of gonadotropin-releasing hormone (GnRH). That pulsing rhythm is what keeps the reproductive axis running.

The genetic evidence is compelling. In humans, loss-of-function mutations in either the gene for neurokinin B (TAC3) or its receptor (TACR3) result in a condition marked by absent or delayed puberty and low reproductive-hormone levels. Rescue experiments in rodents—restoring the relevant gene specifically in these neurons—reinstated the pulsing signal, offering direct evidence that KNDy neurons are the pulse generator. It's a clean illustration of how one tachykinin, acting on one receptor, anchors an entire physiological rhythm.

Why Researchers Study This Family

The short answer: the tachykinin system is a long-running drug-target story, and the way that story unfolded is instructive in its own right.

The clearest clinical success came from blocking the NK1 receptor. The approved antiemetic medicines aprepitant and fosaprepitant—distinct pharmaceutical products, not research-grade material—work by blocking substance P at NK1, and they're used against chemotherapy-related nausea and vomiting, as reviewed in the literature on neurokinin receptors as drug targets. On the NK3 side, antagonists have been investigated for postmenopausal hot flashes and for settings where suppressing gonadotropin signaling is of interest—a direct outgrowth of the KNDy story above.

We think the honest footnote matters here. Despite striking results in animal models of arthritis, colitis, and airway inflammation, NK-receptor antagonists largely failed to show benefit as anti-inflammatory or pain medicines in human trials. That gap between robust animal data and disappointing clinical results is a recurring lesson in translational pharmacology, and it's part of why the family is still actively studied rather than treated as a closed book.

Frequently Asked Questions

What are the tachykinins?

Tachykinins are a family of signaling peptides in the nervous and immune systems. In mammals the three best-characterized members are substance P, neurokinin A, and neurokinin B. They are grouped together because they share the same C-terminal chemical signature and act on the same set of receptors—a structural relationship researchers use to define the family.

What is the difference between substance P, neurokinin A, and neurokinin B?

All three share the conserved FxGLM C-terminal motif but differ in their N-terminal sequences, which is what steers each toward a different receptor. Substance P and neurokinin A are both encoded by the TAC1 gene, while neurokinin B comes from a separate gene, TAC3. In binding studies substance P prefers the NK1 receptor, neurokinin A the NK2 receptor, and neurokinin B the NK3 receptor.

What are NK1, NK2, and NK3 receptors?

They are three G-protein-coupled receptors that the tachykinins act on. Each shows a preference for one peptide: NK1 for substance P, NK2 for neurokinin A, and NK3 for neurokinin B. Because the peptides share a common active ending, these preferences are relative rather than absolute, and each receptor can respond to more than one tachykinin with different potencies.

Why is the FxGLM motif important?

FxGLM is the shared five-residue C-terminal sequence (Phe-X-Gly-Leu-Met) ending in an amidated methionine that every tachykinin carries. Structural studies show this ending reaches deep into the receptor and drives activation, while the residues in front of it determine which receptor a given peptide prefers. It is the structural feature that unites the family.

Putting It All Together

The tachykinins are a tidy lesson in how structure defines a peptide family. One shared ending—the amidated FxGLM motif—makes three otherwise different peptides speak the same molecular language, while the residues in front of that motif steer substance P, neurokinin A, and neurokinin B toward the NK1, NK2, and NK3 receptors respectively. From spinal pain circuits to the hypothalamic clock that paces reproduction, this single family reaches into a remarkable range of biology, which is exactly why it remains one of the most studied neuropeptide systems in the lab. If you found this useful, the rest of our peptide-family series traces the same structure-defines-function logic across other groups of research compounds.

For research use only. Not for human or animal consumption of any kind. The information in this article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The statements made have not been evaluated by the U.S. Food and Drug Administration. These products are NOT FDA APPROVED. Please consult with a licensed healthcare professional before making any decisions regarding your health or research.

Optides LLC is a chemical supplier. Optides LLC is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic Act. Optides LLC is not an outsourcing facility as defined under 503B of the Federal Food, Drug, and Cosmetic Act.